KBY Biotech Indexv0.0.34
Search
← Pipeline|Sovacapivasertib

Sovacapivasertib

Phase 3
AMG-295
By Amgen
Source: Trial-derived·Trials: 4
Modality
siRNA
MOA
ALKi
Target
WEE1
Pathway
Epigenetic
CFSchizophreniaCRC
Development Pipeline
Preclinical
~Sep 2012
→ ~Dec 2013
Phase 1
~Mar 2014
→ ~Jun 2015
Phase 2
~Sep 2015
→ ~Dec 2016
Phase 3
Mar 2017
→ Dec 2031
Phase 3Current
NCT07697567
663 pts·CRC
2025-09→2030-04·Not yet recruiting
NCT06826422
2,295 pts·Schizophrenia
2025-02→2028-09·Not yet recruiting
NCT03234326
173 pts·Schizophrenia
2025-12→2031-12·Recruiting
+1 more trial
4,464 total pts2 indications
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (4)
2028-09-072.4y awayPh3 Readout· Schizophrenia
2030-04-184.0y awayPh3 Readout· CRC
2030-10-204.6y awayPh3 Readout· CRC
2031-12-015.7y awayPh3 Readout· Schizophrenia
Trial Timeline
2017Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
P3
Termina…
P3
Not yet…
P3
Not yet…
P3
Recruit…
Catalysts
Ph3 Readout
2028-09-07 · 2.4y away
Schizophrenia
Ph3 Readout
2030-04-18 · 4.0y away
CRC
Ph3 Readout
2030-10-20 · 4.6y away
CRC
Ph3 Readout
2031-12-01 · 5.7y away
Schizophrenia
RecruitingTerminatedNot yet recruiting|StartCompletionToday
Trials (4)
NCTPhaseIndicationStatusNEP
NCT07697567Phase 3CRCNot yet recr...663DOR
NCT06826422Phase 3SchizophreniaNot yet recr...2295Mayo
NCT03234326Phase 3SchizophreniaRecruiting173BodyWt
NCT08722519Phase 3CRCTerminated1333NT-proBNP
Competitors (10)
DrugCompanyPhaseTargetMOA
MiriosocimabPfizerPhase 1PARPALKi
MRK-7739Merck & CoPreclinicalIL-23ALKi
BMY-2495Bristol-Myers SquibbPhase 3KRASG12DALKi
TAK-2403TakedaPhase 2WEE1BTKi
DSN-5254Daiichi SankyoPhase 1B7-H3ALKi
ZanuratamabGilead SciencesPhase 1/2CDK2ALKi
GIL-2445Gilead SciencesPhase 2/3PSMAALKi
ALN-3284AlnylamPhase 2/3CDK2ALKi
FixaglumideGenmabPhase 2/3WEE1KIF18Ai
NidasacituzumabUnited TherapeuticsPhase 1/2TIM-3ALKi